Verathon Carbon Reduction Plan

30th March 2024

Commitment to Achieving Net Zero:

Verathon Medical UK Ltd. is committed to achieving Net Zero emissions by 2050 or earlier, using 2023 as the base year. Furthermore, Verathon Inc. is in the process of determining its comprehensive global Scope 1-3 emissions for 2023 ahead of committing to Net Zero. Therefore, the Carbon Reduction Plan outlined below pertains only to Verathon Medical UK Ltd. operations at this time.

Baseline Emissions Footprint:

The baseline emissions reported below serve as a record of the greenhouse gases emitted prior to implementing any emissions reduction strategies. These baseline emissions serve as the benchmark against which reductions in emissions can be assessed.

All emissions reported below and going forward are expressed in CO₂ equivalent (CO₂e) to ensure all seven greenhouse gases within the Kyoto Protocol are included. This specifically covers carbon dioxide [CO2], methane [CH4], nitrous oxide [N2O], hydrofluorocarbons [HFCs], perfluorocarbons [PFCs], sulphur hexafluoride [SF6] and nitrogen trifluoride [NF3]).

Seismic Change Sustainability Ltd. has reviewed all calculations and reduction measures outlined in this plan to ensure accurate reporting of our UK carbon footprint.

Verathon Inc. Global Headquarters 20001 North Creek Parkway Bothell, WA 98011 USA

Tel: +1 425 867 1348 Fax: +1 425 883 2896 Verathon Medical UK Ltd. Rutland House, 148 Edmund Street Birmingham, B3 2JR United Kingdom VAT Number: 727 2900 36

VAI Number: 727 2900 36 Company Registration Number: 03867024 Tel: +44 20 8080 6556 Fax: +44 1844 299 218 Verathon Medical (Europe) B.V. Willem Fenengastraat 13 1096 BL Amsterdam The Netherlands Tel: +31 (0) 20 210 30 91 verathon.com

Baseline Year: 2023

Additional details relating to the baseline emission calculations.

2023 was selected as a base year as this was the first year complete Scope 1-3 emissions were calculated. All emissions reported below are specific to the activities of Verathon Medical UK Ltd. only. Because our business does not lease or own facilities or own vehicles in the UK, there are no Scope 1 and 2 emissions to report concerning a specific location or market.

In line with the PPN 06/21 requirements, the UK Scope 3 emissions included within our Net Zero commitment cover the following categories from the GHG Protocol's Corporate Value Chain Scope 3 Standard¹:

- Business Travel: Employee vehicles and third-party transport providers.
- Downstream Transportation and Distribution.
- Downstream Leased Assets: Leased vehicles.

Emissions relating to the following Scope 3 sources are not included in our Net Zero commitment as they are not relevant to our UK activities:

- Employee Commuting: Not relevant as all employee travel in the UK is reimbursed and captured within Business Travel.
- Waste Generation in Operations: Not relevant as we do not own or lease UK facilities.
- Upstream Transportation: Not relevant as our tier 1 suppliers are not based in the UK.

Baseline year emissions: 2023	
Scope	Total (tCO ₂ e)
Scope 1	0
Scope 2	0
Scope 3 (Included Sources)	Business Travel: 201 Downstream Transportation and Distribution: 373 Downstream Leased Assets: 25
Total Emissions	600

Baseline year emissions: 2023

¹ Corporate Value Chain (Scope 3) Standard | GHG Protocol


Verathon Inc. Global Headquarters 20001 North Creek Parkway Bothell, WA 98011 USA

Tel: +1 425 867 1348 Fax: +1 425 883 2896 Verathon Medical UK Ltd. Rutland House, 148 Edmund Street Birmingham, B3 2JR United Kingdom VAT Number: 727 2900 36 Company Registration Number: 03867024 Tel: +44 20 8080 6556 Fax: +44 1844 299 218 Verathon Medical (Europe) B.V. Willem Fenengastraat 13 1096 BL Amsterdam The Netherlands Tel: +31 (0) 20 210 30 91 Fax: +31 (0) 20 210 30 92

verathon.com

Current Emissions Reporting:

Reporting Year: 2023	
Scope	Total (tCO ₂ e)
Scope 1	0
Scope 2	0
Scope 3 (Included Sources)	Business Travel: 201 Downstream Transportation and Distribution: 373 Downstream Leased Assets: 25
Total Emissions	600



In 2023, our baseline and current reporting year, 62% of Scope 3 emissions were associated with downstream transportation and distribution, 34% were associated with business travel and 4% were associated with downstream leased assets.

Verathon Inc. Global Headquarters 20001 North Creek Parkway Bothell, WA 98011 USA

Tel: +1 425 867 1348 Fax: +1 425 883 2896 Verathon Medical UK Ltd. Rutland House, 148 Edmund Street Birmingham, B3 2JR United Kingdom

VAT Number: 727 2900 36 Company Registration Number: 03867024 Tel: +44 20 8080 6556

Fax: +44 1844 299 218

Verathon Medical (Europe) B.V. Willem Fenengastraat 13 1096 BL Amsterdam The Netherlands Tel: +31 (0) 20 210 30 91 verathon.com


Emissions Reduction Targets:

To continue our progress toward achieving Net Zero Verathon Medical UK Ltd. is committed to Net Zero emissions by 2050 or earlier.

We project that carbon emissions will decrease over the next five years to 541 tCO₂e by 2028, a reduction of 10%.

After a detailed review of our carbon footprint, and the reduction levers currently available to our business and suppliers, our Carbon Reduction Plan does not yet take us to Net Zero. This is based on our assessment of supplier commitments plus the fact that much of the technology required to achieve this goal is still in its infancy.

To ensure we drive emissions to zero, we will annually review and update our Carbon Reduction Plan to identify further levers we can pull to achieve our Net Zero commitment.



Verathon Inc. **Global Headquarters** 20001 North Creek Parkway Bothell, WA 98011 USA

Tel: +1 425 867 1348 Fax: +1 425 883 2896

Verathon Medical UK Ltd. Rutland House, 148 Edmund Street Birmingham, B3 2JR United Kingdom VAT Number: 727 2900 36 Company Registration Number: 03867024

Tel: +44 20 8080 6556 Fax: +44 1844 299 218 Verathon Medical (Europe) B.V. Willem Fenengastraat 13 1096 BL Amsterdam The Netherlands Tel: +31 (0) 20 210 30 91 Fax: +31 (0) 20 210 30 92

verathon.com

Carbon Reduction Projects:

2023 was the first year we collected data and calculated Scope 1-3 emissions for our UK operations. As this was our initial year for such an analysis, we currently do not have any carbon reduction initiatives to report based on this 2023 baseline.

Moving forward, we will implement the following measures to achieve our Net Zero commitment and target:

- Continue to collect data, and report Scope 1-3 emissions annually across our UK operations.
- Improve data quality by collecting primary supplier data as this is a key lever to achieve our reduction goals.
- Proactively partner with suppliers that match our Net Zero ambition to facilitate highquality data provision and year-on-year emission reductions.
- Transition our leased fleet to electric vehicles powered by 100% renewable electricity over the commitment window.
- Where possible transition to sea from air freight and where this is not practical, use air transportation suppliers committed to the use of sustainable aviation fuel.
- Continually review and update our Carbon Reduction Plan to identify further levers we can pull to reduce emissions.
- Once our reduction goals have been achieved, we will look to offset residual emissions.

Verathon Inc. Global Headquarters 20001 North Creek Parkway Bothell, WA 98011 USA

Tel: +1 425 867 1348 Fax: +1 425 883 2896 Verathon Medical UK Ltd. Rutland House, 148 Edmund Street Birmingham, B3 2JR United Kingdom

VAT Number: 727 2900 36 Company Registration Number: 03867024 Tel: +44 20 8080 6556

Fax: +44 1844 299 218

Verathon Medical (Europe) B.V. Willem Fenengastraat 13 1096 BL Amsterdam The Netherlands Tel: +31 (0) 20 210 30 91 verathon.com

Declaration and Sign-off:

This Carbon Reduction Plan has been completed in accordance with PPN 06/21, the associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard². These also use the appropriate Government emission conversion factors for greenhouse gas company reporting³.

Scope 1 and Scope 2 emissions have been reported following the SECR requirements, and the required subset of Scope 3 emissions have been reported following the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard⁴.

Signed on behand of Verathon Inc.:

Earl Thompson

Earl Thompson President

Jon Stevens

Jon Stevens Vice President of Quality & Regulatory

² <u>https://ghgprotocol.org/corporate-standard</u>

- ³ https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting
- ⁴ <u>https://ghgprotocol.org/standards/scope-3-standard</u>

Verathon Inc. Global Headquarters 20001 North Creek Parkway Bothell, WA 98011 USA

Tel: +1 425 867 1348 Fax: +1 425 883 2896 Verathon Medical UK Ltd. Rutland House, 148 Edmund Street Birmingham, B3 2JR United Kingdom VAT Number: 727 2900 36 Company Registration Number: 03867024 Tel: +44 20 8080 6556 Fax: +44 1844 299 218 Verathon Medical (Europe) B.V. Willem Fenengastraat 13 1096 BL Amsterdam The Netherlands Tel: +31 (0) 20 210 30 91 verathon.com